Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $1.94 Million Stake in Solventum Co. (NYSE:SOLV)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lowered its holdings in shares of Solventum Co. (NYSE:SOLV) by 2.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,386 shares of the company’s stock after selling 692 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Solventum were worth $1,941,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of Solventum during the 3rd quarter valued at about $231,000. Intech Investment Management LLC acquired a new stake in Solventum during the third quarter valued at approximately $317,000. Landscape Capital Management L.L.C. bought a new stake in shares of Solventum in the 3rd quarter valued at approximately $227,000. Cerity Partners LLC raised its holdings in shares of Solventum by 27.4% in the 3rd quarter. Cerity Partners LLC now owns 52,719 shares of the company’s stock worth $3,676,000 after buying an additional 11,337 shares in the last quarter. Finally, Swedbank AB lifted its position in shares of Solventum by 20.3% during the 3rd quarter. Swedbank AB now owns 107,197 shares of the company’s stock worth $7,474,000 after buying an additional 18,108 shares during the period.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on SOLV. Bank of America upped their price target on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, February 26th. Mizuho increased their target price on shares of Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, March 3rd. Piper Sandler lifted their price target on shares of Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a report on Friday, February 28th. The Goldman Sachs Group upped their price objective on shares of Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research note on Monday, March 3rd. Finally, Morgan Stanley lifted their target price on shares of Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $79.86.

Solventum Price Performance

SOLV opened at $74.87 on Wednesday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The stock has a market capitalization of $12.95 billion and a P/E ratio of 27.23. The company’s 50 day simple moving average is $75.38 and its 200-day simple moving average is $71.73. Solventum Co. has a one year low of $47.16 and a one year high of $85.92.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.